List view / Grid view
Landmark, decade-only investment plan aims to support the pharma company’s…
Landmark, decade-only investment plan aims to support the pharma company’s 2030 revenue objective of $80 billion.
The move is part of biopharma's $50 billion pledge to…
The move is part of biopharma's $50 billion pledge to US medicines manufacturing and R&D.
The company will now put a total of $4.5 billion…
The company will now put a total of $4.5 billion into the Virginia site, expanding its remit to include active pharmaceutical ingredients for cancer drugs.
Under growing global competition, this development highlights potential challenges for…
Under growing global competition, this development highlights potential challenges for the UK to uphold large-scale pharmaceutical investments.
The US$570m investment will contribute to advancing AstraZeneca’s global clinical…
The US$570m investment will contribute to advancing AstraZeneca’s global clinical pipeline, a key goal of its strategy to 2030.
This investment supports AstraZeneca’s strategy to drive the biopharma company's…
This investment supports AstraZeneca’s strategy to drive the biopharma company's development in the US.
The new manufacturing facility for antibody drug conjugates (ADCs) will…
The new manufacturing facility for antibody drug conjugates (ADCs) will be designed to have zero carbon emissions when operational, AstraZeneca stated.
The new industry collaboration aims to help decarbonise the global…
The new industry collaboration aims to help decarbonise the global supply chain by focusing on the energy-intensive pharmaceutical manufacturing that takes place in China and India.
Johnson & Johnson have been shifted from the top position…
Johnson & Johnson have been shifted from the top position in the market capitalisation ranking for the first time, due to Eli Lilly having the largest growth during Q2 2023, research shows.
Former Senior Vice President, Head of Research and Product Development…
Former Senior Vice President, Head of Research and Product Development of Alexion, will succeed Mene Pangalos as Executive Vice President, BioPharmaceuticals R&D at AstraZeneca.
With two knighthoods in the last month, here EPR discusses…
With two knighthoods in the last month, here EPR discusses five developments in the drug development community’s C-suite.
AstraZeneca has announced plans to invest in a new facility,…
AstraZeneca has announced plans to invest in a new facility, uniting its R&D activities with commercial and corporate functions in Boston, US.
H1 financial results show AstraZeneca’s revenues grew by 23 percent…
H1 financial results show AstraZeneca’s revenues grew by 23 percent in 2021, with $14.37 billion attributed to activities aside from COVID-19 vaccine sales.
After manufacturing delays, AstraZeneca will now provide the EU with…
After manufacturing delays, AstraZeneca will now provide the EU with the 40 million COVID-19 vaccine doses it originally agreed to supply.
Interim analysis shows AZD1222 vaccine is effective at preventing COVID-19,…
Interim analysis shows AZD1222 vaccine is effective at preventing COVID-19, with no severe cases or hospitalisations reported more than 21 days after first injection.
